	US 12,257,263 B2
	Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
Tiang Hin Jerry Tan, Singapore (SG); and Yong Ming Por, Singapore (SG)
Assigned to Tarsus Pharmaceuticals, Inc., Irvine, CA (US)
Filed by Tarsus Pharmaceuticals, Inc., Irvine (CA)
Filed on Jan. 7, 2022, as Appl. No. 17/570,745.
Application 17/570,745 is a continuation of application No. 16/725,761, filed on Dec. 23, 2019, abandoned.
Application 16/725,761 is a continuation of application No. 15/501,420, abandoned, previously published as PCT/SG2014/000371, filed on Aug. 4, 2014.
Prior Publication US 2022/0125817 A1, Apr. 28, 2022
Int. Cl. A61K 31/7048 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/65 (2006.01); A61K 45/06 (2006.01); A61K 47/06 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01); A61K 47/34 (2017.01); A61K 47/44 (2017.01)

CPC A61K 31/7048 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 31/65 (2013.01); A61K 45/06 (2013.01); A61K 47/06 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); A61K 47/44 (2013.01)]

7 Claims

1. A method for the treatment of demodex blepharitis and eyelid crusting, comprising:

identifying a presence of demodex mites in eyelash follicles of an individual;

topically administering every night for a month onto the eyelash follicles of the individual in need of such treatment and removing with water in the morning, a topical pharmaceutical composition formulated as an emulsion, comprising:

an effective amount of ivermectin and an additional antibiotic selected from the group consisting of a tetracycline, an oxytetracycline, a macrolide, a fluoroquinolone, an aminoglycoside and metronidazole;

water;

a humectant comprising sorbitol;

a mixture of emollients comprising cyclopentasiloxane and ethylhexyl stearate;

an additional agent as emulsifier;

a mixture of preservatives comprising methylchloroisothiazolinone and disodium EDTA;

an antioxidant comprising tocopheryl acetate; and

a solvent comprising propylene glycol;

wherein the topically administering is sufficient to eliminate the presence of demodex mites in the eyelash follicles of the individual.